Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Dianthus Therapeutics (DNTH) over the last 6 years, with Q3 2025 value amounting to $6.4 million.

  • Dianthus Therapeutics' Gains from Investment Securities rose 4114.11% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 4114.11%. This contributed to the annual value of $4.5 million for FY2024, which is 15720.3% up from last year.
  • Dianthus Therapeutics' Gains from Investment Securities amounted to $6.4 million in Q3 2025, which was up 4114.11% from $6.2 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Gains from Investment Securities peaked at $6.4 million during Q3 2025, and registered a low of -$3.3 million during Q2 2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was $1.1 million (2023), whereas its average is $2.1 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' Gains from Investment Securities soared by 115434.78% in 2024, and later crashed by 9032.26% in 2025.
  • Quarter analysis of 3 years shows Dianthus Therapeutics' Gains from Investment Securities stood at -$46000.0 in 2023, then surged by 1154.35% to $485000.0 in 2024, then surged by 1209.55% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $6.2 million for Q2 2025, and $45000.0 during Q1 2025.